Comparison of Tamsulosin, Nifedipine, and Placebo for Ureteric Colic

Gottlieb, Michael; Nakitende, Damali

doi:10.1017/cem.2015.105

Cited by 7 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, infection with H. pylori was demonstrated to lead to gastritis and stomach cancer. 269,270 IBD was not sufficient to induce CRC in the absence of intestinal microbiota or microbial products, 271 and the use of a common antimicrobial additive Fig. 2 Inflammatory signaling pathways involved in cancer development.…”

Section: Cancer-promoting Inflammationmentioning

confidence: 99%

Inflammation and tumor progression: signaling pathways and targeted intervention

Zhao

Yan

et al. 2021

Sig Transduct Target Ther

1,265

682

View full text Add to dashboard Cite

Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses tumor progression, potentially displaying opposing effects on therapeutic outcomes. Chronic inflammation facilitates tumor progression and treatment resistance, whereas induction of acute inflammatory reactions often stimulates the maturation of dendritic cells (DCs) and antigen presentation, leading to anti-tumor immune responses. In addition, multiple signaling pathways, such as nuclear factor kappa B (NF-kB), Janus kinase/signal transducers and activators of transcription (JAK-STAT), toll-like receptor (TLR) pathways, cGAS/STING, and mitogen-activated protein kinase (MAPK); inflammatory factors, including cytokines (e.g., interleukin (IL), interferon (IFN), and tumor necrosis factor (TNF)-α), chemokines (e.g., C-C motif chemokine ligands (CCLs) and C-X-C motif chemokine ligands (CXCLs)), growth factors (e.g., vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β), and inflammasome; as well as inflammatory metabolites including prostaglandins, leukotrienes, thromboxane, and specialized proresolving mediators (SPM), have been identified as pivotal regulators of the initiation and resolution of inflammation. Nowadays, local irradiation, recombinant cytokines, neutralizing antibodies, small-molecule inhibitors, DC vaccines, oncolytic viruses, TLR agonists, and SPM have been developed to specifically modulate inflammation in cancer therapy, with some of these factors already undergoing clinical trials. Herein, we discuss the initiation and resolution of inflammation, the crosstalk between tumor development and inflammatory processes. We also highlight potential targets for harnessing inflammation in the treatment of cancer.

show abstract

Section: Cancer-promoting Inflammationmentioning

confidence: 99%

Inflammation and tumor progression: signaling pathways and targeted intervention

Zhao

Yan

et al. 2021

Sig Transduct Target Ther

1,265

682

View full text Add to dashboard Cite

show abstract

“…21 However, Gottlieb and Nakitende recently performed a metaanalysis of tamsulosin, nifedipine, and placebo in treatment of ureteric colic; they found that combination tamsulosin and nifedipine therapy was not more effective than placebo in reducing the need for urologic intervention after 4 weeks of treatment among patients with acute ureteric colic. 12 Thus, additional clinical studies are needed to confirm the efficacy of nifedipine in treatment of ureteric stones.…”

Section: Discussionmentioning

confidence: 99%

“…10 Nifedipine continues to be used for clinical treatment of ureteral stones. 11,12 Several studies have shown that terazosin, an a-receptor antagonist for benign prostatic hyperplasia, 13 can be used to promote stone discharge in treatment of ureteral stones. 14,15 Moreover, terazosin is reportedly safe and effective in treatment of distal ureteral stones, especially stones >5 mm.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

Objective: To investigate the efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. Methods: This prospective single-blinded randomized study enrolled 165 patients undergoing transurethral ureteroscopic lithotripsy in our hospital. Patients were randomized into three groups: control, terazosin, and combination treatment (terazosin and nifedipine). Stone discharge rates and times were recorded, along with side effects and complications. Visual Analogue Scale (VAS) score was used to evaluate pain for 7 days postoperatively. International Prostatic Symptoms Score (IPSS) was used to evaluate prostatic function; quality of life (QOL) was evaluated preoperatively and at 7 days postoperatively. Results: The stone discharge rate was significantly higher in the combination group than in other groups; moreover, mean discharge time was shorter in the combination group. Beginning at 3 days postoperatively, VAS scores were dramatically lower in the combination group than in other groups; IPSS and QOL scores were also lower in the combination group. Edema recurrence was significantly less common in combination and terazosin groups than in the control group. Side effects were similar among groups. Conclusion: Combination terazosin and nifedipine therapy was safe and effective in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy.

show abstract

“…Seen in the broad context of all clinical trials of linagliptin, alogliptin, and sitagliptin, the increased HHF observed with saxagliptin in the SAVOR TIMI 53 trial is likely a compound-specific, rather than a general class effect ( Home, 2019 ). Conclusions about the class-specific effects of DPP4i should be done carefully, due to the structural variations of different DPP4i and the resulting differences in the selectivity toward DPP8 and DPP9 ( Riche and Davis, 2015 ). These differences may lead to altered adverse effect profiles which must be considered for each chemical entity.…”

Section: Dpp4 Inhibitors (Gliptins) In Cardiovascular Diseasementioning

confidence: 99%

Repurposing Antidiabetic Drugs for Cardiovascular Disease

et al. 2020

View full text Add to dashboard Cite

Metabolic diseases and diabetes represent an increasing global challenge for human health care. As associated with a strongly elevated risk of developing atherosclerosis, kidney failure and death from myocardial infarction or stroke, the treatment of diabetes requires a more effective approach than lowering blood glucose levels. This review summarizes the evidence for the cardioprotective benefits induced by antidiabetic agents, including sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1-RA), along with sometimes conversely discussed effects of dipeptidyl peptidase-4 inhibitor (DPP4i) and metformin in patients with high cardiovascular risk with or without type 2 diabetes. Moreover, the proposed mechanisms of the different drugs are described based on the results of preclinical studies. Recent cardiovascular outcome trials unexpectedly confirmed a beneficial effect of GLP-1RA and SGLT2i in type 2 diabetes patients with high cardiovascular risk and with standard care, which was independent of glycaemic control. These results triggered a plethora of studies to clarify the underlying mechanisms and the relevance of these effects. Taken together, the available data strongly highlight the potential of repurposing the original antidiabetics GLP1-RA and SGLT2i to improve cardiovascular outcome even in non-diabetic patients with cardiovascular diseases.

show abstract

Comparison of Tamsulosin, Nifedipine, and Placebo for Ureteric Colic

Abstract: Clinical Question

Cited by 7 publications

References 4 publications

Inflammation and tumor progression: signaling pathways and targeted intervention

Inflammation and tumor progression: signaling pathways and targeted intervention

Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy

Repurposing Antidiabetic Drugs for Cardiovascular Disease

Contact Info

Product

Resources

About